# TCF7L2
**TCF7L2** (transcription factor 7 like 2), formerly known as T-cell factor 4 or TCF-4, is a human protein-coding gene and transcription factor that contains a high mobility group (HMG) box [DNA-binding domain](https://www.edgepedia.org/dna-binding-domain) and plays a key role in the canonical [Wnt signaling pathway](https://www.edgepedia.org/wnt-signaling-pathway), with established involvement in blood glucose homeostasis.[1](https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&list_uids=6934) It is one of four mammalian TCF/LEF genes (TCF7, [TCF7L1](https://www.edgepedia.org/tcf7l1), TCF7L2, and LEF1) that serve as the nuclear effectors of Wnt/β-catenin signaling, and it harbors the strongest common genetic association with type 2 diabetes identified to date.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC6165711/) • [3](https://pubmed.ncbi.nlm.nih.gov/40675550/)
| Key fact | Detail |
|---|---|
| Gene | TCF7L2, Gene ID 6934, protein coding, HGNC:11641; also known as TCF4/TCF-4, a symbol it shares with the unrelated TCF4 gene (Gene ID 6925)[1](https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&list_uids=6934) |
| Function | HMG box transcription factor, downstream effector of canonical Wnt/β-catenin signaling controlling cell fate and homeostasis[1](https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&list_uids=6934) • [4](https://pubmed.ncbi.nlm.nih.gov/20654575/) |
| DNA binding | HMG box recognizes the Wnt response element consensus 5′-ACATCAAAG-3′, contacting the DNA minor groove and bending the double helix[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/) |
| Splicing | The human and mouse genes consist of 17 exons; alternative splicing generates E, S, and M isoform classes with divergent C-termini[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847248/) |
| Diabetes risk | rs7903146 (C/T) is the most impactful single genetic risk variant for type 2 diabetes; the T allele is the risk allele[7](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16193) |
| Effect size | Allelic risk of 1.56 (P = 4.7 × 10−18) in the original European case-control study; one allele confers about 40% relative risk, two copies about 80%[8](https://diabetesjournals.org/care/article/32/6/1107/28075/Genetic-Architecture-of-Type-2-Diabetes-Recent) |
| Knockout phenotype | TCF7L2-knockout mice die 24 hours after birth and lack the intestinal epithelial stem cell compartment[9](https://diabetesjournals.org/diabetes/article/70/6/1220/137694/The-Role-of-TCF7L2-in-Type-2-Diabetes) |
## Role in Wnt signaling
In the canonical Wnt pathway, β-catenin accumulates in the cytoplasm and nucleus when the destruction complex is inhibited, and in the nucleus it associates with TCF proteins to activate transcription of Wnt target genes.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/) In the absence of Wnt signaling, TCF7L2 and other HMG box TCF proteins function in the nucleus as transcriptional repressors of Wnt target genes, interacting with Groucho/TLE corepressors.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC3429047/) • [5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/) Wnt signals therefore switch TCF/LEF factors from repression to activation, mediated in part by nuclear β-catenin binding and recruitment of co-activator complexes.[11](https://pubmed.ncbi.nlm.nih.gov/22111711/)
Full-length TCF7L2 contains several conserved functional domains: the β-catenin-binding domain, the HMG box DNA-binding domain, a nuclear localization signal, the C-clamp DNA-binding motif, and the domain mediating interaction with the [C-terminal binding protein](https://www.edgepedia.org/c-terminal-binding-protein) (CtBP).[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/) The E-tail isoforms encode two copies of the PLDLS motif that binds the co-repressor CtBP.[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC8651982/) Phosphorylation by NLK at specific sites inhibits DNA binding by TCF7L2, preventing transcriptional activation of canonical Wnt target genes.[13](https://www.genecards.org/card/TCF7L2)
## Alternative splicing and isoforms
**Many isoforms, different functions.** The human and mouse [TCF4](https://www.edgepedia.org/tcf4) genes consist of 17 exons, and extensive alternative splicing of exons 13 through 16 generates isoforms with highly diverging C-termini.[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847248/) Only the E-type variants harbor a complete C-clamp and the two CtBP-binding motifs; other isoforms lack the CtBP-binding sites and have either no C-clamp (M variants) or an incomplete one (S variants).[6](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847248/) These isoforms differ in DNA binding and cofactor binding, which changes target gene activation or selection.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/)
Splicing is tissue-specific. One survey of up to 380 samples from eight human tissues found that expression of TCF7L2 alternative exons forms a tissue-specific signature, with a unique splicing form expressed in pancreatic islets, pancreas, and colon but not in the other tissues examined; its expression in glucose-stimulated islets correlated strongly with proinsulin expression (r2 = 0.84–0.90).[14](https://pmc.ncbi.nlm.nih.gov/articles/PMC2748888/) A study across six tissues observed 32 transcript isoforms, 10 of which appeared in at least 5% of clones from at least one tissue.[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841530/) Lithium, a Wnt-signaling activator, increases TCF7L2 mRNA levels and induces an isoform switch favoring short forms lacking the C-terminal domains, through a GSK3β-independent modulation of [RNA splicing](https://www.edgepedia.org/rna-splicing).[4](https://pubmed.ncbi.nlm.nih.gov/20654575/)
## Type 2 diabetes genetics
The link to diabetes came from linkage studies in Icelanders that identified a peak on chromosome arm 10q25.3, and fine-mapping within that region identified TCF7L2 as the candidate gene.[8](https://diabetesjournals.org/care/article/32/6/1107/28075/Genetic-Architecture-of-Type-2-Diabetes-Recent) • [14](https://pmc.ncbi.nlm.nih.gov/articles/PMC2748888/) In a subsequent case-control study of 3,774 subjects from Iceland, Denmark, and the United States, the estimated allelic risk was 1.56 (P = 4.7 × 10−18), with an additive effect: one risk allele conferring about 40% relative risk of diabetes and two copies about 80%.[8](https://diabetesjournals.org/care/article/32/6/1107/28075/Genetic-Architecture-of-Type-2-Diabetes-Recent) In French cohorts, the rs7903146 T allele and the rs12255372 T allele gave allelic odds ratios of 1.69 and 1.60 respectively, rising to 1.89 and 1.79 in nonobese diabetic subjects.[16](https://pubmed.ncbi.nlm.nih.gov/17003360/) The Diabetes Prevention Program found the common allele increases risk approximately 1.45-fold in heterozygotes and 2.41-fold in homozygotes.[17](https://www.nejm.org/doi/pdf/10.1056/NEJMoa062418)
**How the variant acts.** rs7903146 lies in a non-coding region, so it does not change the protein sequence; bioinformatic analyses place it within an active intronic regulatory region with chromatin accessibility, enhancer-associated histone marks, and transcription factor occupancy, and eQTL (DNA variant affecting a gene's expression level) analyses show tissue-specific effects on TCF7L2 expression.[18](https://pmc.ncbi.nlm.nih.gov/articles/PMC13465029/) Various lines of evidence suggest the mechanisms involve the enteroinsular axis, impaired insulin secretion, and possibly reduced β-cell proliferation.[8](https://diabetesjournals.org/care/article/32/6/1107/28075/Genetic-Architecture-of-Type-2-Diabetes-Recent) TCF7L2 regulates the preproglucagon (GCG) gene that encodes glucagon-like peptide 1 (GLP-1), suggesting that variants modifying GLP-1 levels in endocrine cells could influence diabetes susceptibility.[9](https://diabetesjournals.org/diabetes/article/70/6/1220/137694/The-Role-of-TCF7L2-in-Type-2-Diabetes) A longitudinal study of 128 subjects followed three years apart found that glucose tolerance worsened in TT homozygotes, accompanied by impaired postchallenge glucagon suppression with appropriate β-cell responsivity, suggesting α-cell abnormalities occur early and may precede β-cell dysfunction.[19](https://pubmed.ncbi.nlm.nih.gov/38869455/)
**Clinical picture in carriers.** A 2025 analysis of 9,231 individuals with type 2 diabetes followed up to 10 years found that each rs7903146 T allele was associated with 0.6 kg/m2 lower BMI, 1.4 cm smaller waist circumference, 5.6% lower insulin secretion, and 5.0% higher insulin sensitivity at diagnosis, and with lower 10-year risks of major adverse cardiovascular events (0.87), myocardial infarction (0.82), and heart failure (0.85), with no significant impact on microvascular complications.[7](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16193) The T allele frequency varies across ethnic groups, being lowest in East Asians and highest in Latin (Brazilian/mixed ancestry) populations.[20](https://pmc.ncbi.nlm.nih.gov/articles/PMC12385235/) Unlike type 2 diabetes, a meta-analysis found that rs7903146 and rs12255372 do not modulate polycystic ovary syndrome risk.[21](https://pubmed.ncbi.nlm.nih.gov/39762965/)
## Metabolic and developmental roles
TCF7L2 is expressed in most human tissues, including mature pancreatic beta cells, with the exception of skeletal muscle.[16](https://pubmed.ncbi.nlm.nih.gov/17003360/) Beyond the pancreas, liver-specific deletion of Tcf7l2 in mice had little effect on plasma glucose but disrupted hepatic zonation, collapsing the gradients of gene expression across the liver lobule and disorganizing glutamine metabolism; in parallel, glutamine was the most significantly decreased plasma metabolite in humans carrying the rs7903146 variant.[3](https://pubmed.ncbi.nlm.nih.gov/40675550/) TCF7L2-silencing and ChIP-Seq studies identify it as a key regulator of hepatic glucose metabolism.[9](https://diabetesjournals.org/diabetes/article/70/6/1220/137694/The-Role-of-TCF7L2-in-Type-2-Diabetes)
During rat fetal beta-cell differentiation, TCF7L2 expression mimics the key marker NGN3 (neurogenin 3), suggesting a role in islet development.[16](https://pubmed.ncbi.nlm.nih.gov/17003360/) In the kidney, a β-catenin-driven switch in TCF/LEF binding to DNA target sites promotes commitment of nephron progenitor cells.[22](https://elifesciences.org/articles/64444)
## Cancer
TCF7L2 was initially identified in cancer research and embryologic developmental studies before its link to type 2 diabetes.[23](https://pubmed.ncbi.nlm.nih.gov/34612510/) It belongs to the most frequently mutated genes in colorectal cancer, and tumor-suppressive functions have been proposed; a genome-wide RNAi screen identified TCF7L2 as a transcriptional repressor that decreases Wnt pathway output and restricts colorectal cancer cell growth.[24](https://pmc.ncbi.nlm.nih.gov/articles/PMC7203011/) • [5](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/) TCF7L2-deficient colorectal cancer cells remain viable and proliferate, a fundamental change from the healthy intestinal epithelium, where TCF7L2 is essential.[24](https://pmc.ncbi.nlm.nih.gov/articles/PMC7203011/) In colorectal cancer cell lines, hypoxia induces TCF7L2 upregulation in a HIF-1α-dependent manner, and TCF7L2 promotes proliferation via the PI3K/AKT pathway, with high TCF7L2 linked to poor prognosis.[25](https://www.sciencedirect.com/science/article/pii/S0014482725004689) Common TCF7L2 variants have also been reported in genome-wide association studies of colorectal cancer, and a multicancer signal on chromosome 8q24 drives MYC expression distally via a distant TCF7L2 regulatory element.[26](https://pmc.ncbi.nlm.nih.gov/articles/PMC6702598/)
## References
1. [TCF7L2 transcription factor 7 like 2 [Homo sapiens], NCBI Gene](https://www.ncbi.nlm.nih.gov/gene?cmd=Retrieve&list_uids=6934)
2. [Mechanisms of Wnt signaling and control, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6165711/)
3. [The diabetes gene Tcf7l2 organizes gene expression in the liver and regulates amino acid metabolism, Molecular Metabolism (2025)](https://pubmed.ncbi.nlm.nih.gov/40675550/)
4. [The balance of TCF7L2 variants with differential activities in Wnt-signaling is regulated by lithium in a GSK3beta-independent manner, PubMed](https://pubmed.ncbi.nlm.nih.gov/20654575/)
5. [TCF/LEF Transcription Factors: An Update from the Internet Resources, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4963812/)
6. [Alternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847248/)
7. [Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes, Diabetes Obesity & Metabolism (2025)](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16193)
8. [Genetic Architecture of Type 2 Diabetes: Recent Progress and Clinical Implications, Diabetes Care](https://diabetesjournals.org/care/article/32/6/1107/28075/Genetic-Architecture-of-Type-2-Diabetes-Recent)
9. [The Role of TCF7L2 in Type 2 Diabetes, Diabetes](https://diabetesjournals.org/diabetes/article/70/6/1220/137694/The-Role-of-TCF7L2-in-Type-2-Diabetes)
10. [The role of the Wnt signaling pathway in incretin hormone production and function, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3429047/)
11. [Cell-context dependent TCF/LEF expression and function, PubMed](https://pubmed.ncbi.nlm.nih.gov/22111711/)
12. [T-Cell Factors as Transcriptional Inhibitors: Activities and Regulations in Vertebrate Head Development, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8651982/)
13. [TCF7L2 Gene, GeneCards](https://www.genecards.org/card/TCF7L2)
14. [Tissue-specific alternative splicing of TCF7L2, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC2748888/)
15. [Genotype and Tissue-Specific Effects on Alternative Splicing of the Transcription Factor 7-Like 2 Gene in Humans, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841530/)
16. [Transcription factor TCF7L2 genetic study in the French population, PubMed](https://pubmed.ncbi.nlm.nih.gov/17003360/)
17. [TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program, New England Journal of Medicine](https://www.nejm.org/doi/pdf/10.1056/NEJMoa062418)
18. [Integrative Clinical and Functional Characterization of the TCF7L2 rs7903146 Variant, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC13465029/)
19. [The Longitudinal Effect of Diabetes-Associated Variation in TCF7L2 on Islet Function in Humans, PubMed](https://pubmed.ncbi.nlm.nih.gov/38869455/)
20. [Association of TCF7L2 rs7903146 (C/T) Polymorphism with Type 2 Diabetes Mellitus in a Chinese Population, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12385235/)
21. [Association of TCF7L2 genetic variants rs12255372 and rs7903146 with polycystic ovary syndrome risk: systematic review and meta-analysis, PubMed](https://pubmed.ncbi.nlm.nih.gov/39762965/)
22. [A β-catenin-driven switch in TCF/LEF transcription factor binding promotes commitment of mammalian nephron progenitor cells, eLife](https://elifesciences.org/articles/64444)
23. [The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetes, PubMed](https://pubmed.ncbi.nlm.nih.gov/34612510/)
24. [Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7203011/)
25. [Mechanistic insights into hypoxia-induced TCF7L2 upregulation and its oncogenic effects on colorectal cancer, Experimental Cell Research](https://www.sciencedirect.com/science/article/pii/S0014482725004689)
26. [The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6702598/)
---
*Topic: Encyclopedia › Life and health › Biological foundations › RNA and gene regulation › Transcription and gene regulation › Transcription factor families and specific factors › SOX, HMG-box, and T-box transcription factors*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license